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Introduction
Endometrial cancer (EC) develops in about 142000
women worldwide annually being the reason of death in
about 42000 women. The most common lesions are typ-
ically hormone sensitive and low stage endometrioid
cancer which have an excellent prognosis (EC type 1).
In contrast, EC type 2 (serous carcinoma) is high grade
with a tendency to recur, even at an early stage [1]. 
The RAS family G proteins (N-, H-, and KRAS) are
thought to play a critical role in the regulation of cel-
lular proliferation. On the other hand evaluation of
molecular alterations involved in the regulation of
tumor growth, cell death and markers of cancer pro-
gression have provided the fundamental basis for the
development of molecular targeted therapies [2]. 
Mutations of the KRAS gene have been implicated
in the development of numerous endometrial malig-
nancies [3-7]. The mutation in codon 12 of KRAS has
been found in 10-30% of endometrial carcinomas.
Some studies have indicated that mutations in codon
12 of KRAS are an independent, unfavourable prog-
nostic factor [8-10] while others have not found this
correlation [11-15]. 
A higher prevalence of KRAS mutations in endome-
trial carcinomas in Japan (30%) compared with other
countries (15%) has been indicated [11,12,14]. In addi-
tion, KRAS mutations have been identified in endome-
trial hyperplasias (EH) and more frequently in com-
plex atypical hyperplasias (CAH), which suggests the
KRAS mutations may be a relatively early event in
endometrial carcinogenesis. 
In connection with these data, we investigated
mutation status of codon 12 of KRAS in surgical spec-
imens of endometrial carcinoma and endometrial
hyperplasia using a polymerase chain reaction associ-
ated with restriction fragment length polymorphism
(PCR-RFPL).
Materials and methods
Tissue samples. 49 patients with histologically confirmed diag-
nosis of endometrial carcinoma were enrolled into the study
(mean age ± SD – 62.25 ± 3.75 years). All tumors were staged
according to the criteria of the International Federation of Gyne-
cology and Obstetrics (FIGO). Finally, an additional diagnosed
set of 11 CAH was included. The initial manifestation of all
cases of hyperplasia was an abnormal vaginal bleeding and the
age range of patients was 40-52 years. Serial paraffin sections
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were stained with H+E for light microscopic study. Clinico-
pathological information was obtained from medical charts and
histopathological examination was performed according to the
WHO classification. None of the patients had received radiation
or hormonal therapy prior to surgery. Only 3 patients were pre-
menopausal and the remaining 46 were postmenopausal. 
RFLP. The detection of KRAS mutations at codon 12 was per-
formed by PCR-RFLP method and the results of the detection
were verified by direct sequencing of PCR products. DNA
amplification was performed in 20 μl reaction mixture contain-
ing 10 – 100 ng of genomic DNA isolated from tissue, 1.5 mM
of MgCl2, 0.2 μM of dNTPs (Sigma), 0.2  M of each of the
primers K1 and DD5P and 1.0 U of Taq DNA polymerase
(Sigma) in 1x PCR buffer supplied by the polymerase manufac-
turer. The K1 upstream primer (5'- ACT GAA TAT AAA CTT
GTG GTA GTT GGA CCT -3') was immediately upstream of
KRAS codon 12 and introduced a G to C substitution at the first
position of the codon 11 of KRAS in order to create a BstOI
restriction site (5'-CCT/AGG-3') within the above amplified
fragment which overlapped the first two nucleotides of codon 12
and was lost when codon 12 mutations took place. The down-
stream primer DD5P was as follows: 5'-TCA TGA AAA TGG
TCA GAG AA-3'.
Sequencing. After the initial DNA denaturation at 95°C for 
3 min, PCR was carried out for 40 cycles (94°C for 15 s, 56°C for
15 s, 72°C for 15 s) followed by terminal extension of PCR prod-
ucts at 72°C for 7 minutes. PCR products were then digested with
a restriction endonuclease BstOI. For this purpose, five-micro-
liter aliquots of the post-PCR reaction mixture were digested
with 10 U of the restriction endonuclease BstOI (PROMEGA) in
the appropriate reaction buffer (supplied by the enzyme manu-
facturer) in the final volume of 10 μl at 60°C for 3 h. The addi-
tional aliquot of 5 U of the enzyme was added to the reaction
mixture after the first hour of the digestion. The enzyme recog-
nized the sequence 5'-CCTGG-3', which was present in codon 12
KRAS wild type PCR products, but was absent from the mutant
ones. As a result, only the wild type molecules were digested into
two fragments – 160 bp and 29 bp long. The digestion products
were then electrophoresed on a 6% native polyacrylamide gel,
stained with ethidium bromide and photographed on a ultraviolet
light transilluminator with the use of UVI-KS 400i/Image PC
system. The non-restricted PCR products were 189 bp long,
whereas the wild type codon 12 products, being restricted inside
codon 12 sequence, were 160 bp long. All mutations were then
confirmed by direct sequencing of the PCR products. For this
purpose, antisense strain of PCR products were sequenced with
the antisense primer DD5P, an ABI PRISM BigDye Terminator
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Fig. 1. Examples of mutation analysis of KRAS gene. (A) KRAS codon
12 restriction fragment length polymorphism analysis. Sample 1 – size
marker, samples 2 and 8 – tumors with mutated codon 12 KRAS
sequence, samples 3, 4, 5, 6, 7, 9 – tumors with normal (wild type)
codon 12 KRAS gene sequence. (B) A sequencing electropherogram
with KRAS codon 12 mutant sequence. The letter N indicates the site
of mutation. Antysense strain of the KRAS gene has been sequenced in
this assay.
v.3.1 Cycle Sequencing Ready Reaction  kit (Applied Biosys-
tems) and an automatic ABI PRISM 377 DNA sequencer
(Applied Biosystems). A wild-type control DNA sample (without
KRAS codon 12 mutation) and a known mutation sample were
included in all the experiments. All experiments were duplicated
precisely. 
Ethical issues. The protocol was previously approved by the
Bioethical Committee of the Medical University of Bia³ystok (R-I-
003/177/2004).
Statistical analysis. For statistical analysis, the χ2 test was per-
formed; p<0.05 was considered significant.
Results
The stage of the 49 patients was: Ia – 3 cases, Ib – 10,
Ic – 4, IIa – 20, IIb – 6, IIIa – 4, IIIb – 1 and IIIc – 1
cases. Histologically, 39 of the 49 patients had
endometrioid – type carcinoma, 7 had adenocarcinoma
with squamous differentiation, 1 had papillary serous
carcinoma and 2 had clear cell carcinoma. 28 were well-
differentiated (G1), 14 were moderately differentiated
(G2) and 7 were poorly differentiated (G3). 
KRAS mutation was detected in 7/39 (14.3%) of
tumor specimens and in 2/11 (18.2%) of CAH (Fig. 1).
The results are summarized in Tables 1 and 2.   
Discussion
Although EC is the most common gynecologic cancer
in the developed world, the details of its carcinogene-
sis are still not well known. In the majority of cases,
the neoplasm is histologically diagnosed as the
endometrioid type (type 1) and its stage at the time of
diagnosis is determined as I (FIGO). Some histological
properties of EC have a prognostic value as they are
associated with the risk of metastases, recurrence and
the length of survival. Such prognostic factors include
the histological type, grade, depth of myometrium
infiltration and lymph-vascular space involvement.
Recently, a number of steps in sporadic endometrial
carcinogenesis have been identified. The most impor-
tant basis of understanding molecular events in EC is
that this is a hormone-dependent tumor. Additional
molecular abnormalities include overexpression of
p53 and KRAS point mutations [16,17].
RAS oncogenes are the proven proto-oncogenes in
human activated by point mutation. The three RAS
oncogenes, HRAS, KRAS, and NRAS, share a common
amino acid sequence, with a subtle difference in C-ter-
minal part of the polipeptides. The point mutation in
codon 12 of RAS oncogene changes glycine to other
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Table 1. Distribution of KRAS mutations according to clinicopathological characteristics of the examined tumor specimens.
amino acids except proline, and this transformation
results in carcinogenesis.
KRAS point mutations have been implicated in the
development of atypical endometrial hyperplasia and
EC. These findings suggest that KRAS mutations may
be an early oncogenic event in endometrial carcino-
genesis [18]. In the case of EC, molecular details are
beginning to emerge, which may eventually help
advance our understanding of the complex
histopathology of this disease. The estrogen-related
type 1 EC account for up to 80% of the EC cases and
appear to arise via a progression pathway. Frequently,
the advanced carcinomas are temporally and spatially
associated with complex atypical hyperplasia, which
constitutes a range of heterogeneous precancerous
lesions. Atypical hyperplasia, the most advanced com-
ponent of this histopathologic spectrum, is considered
to be the direct precursor lesion of type 1 EC. Subsets
of type 1 EC were found to contain KRAS mutations
(15-20%). Both of these abnormalities were also
detected in CAH [19]. Fujimoto et al. reported a 22%
KRAS point mutation rate, and this abnormality was
associated with high rate in lymph node metastasis
[20]. Mizuuchi et al. reported KRAS point mutation as
a poor prognostic parameter in EC [9]. Relatively high
incidences of KRAS mutations have been reported for
EC, especially for type 1 carcinoma, suggesting that
mutant KRAS is involved in the development and/or
progression of these tumors [8-10]. In the present
study, no correlation was found between KRAS gene
mutation and age at onset, histological subtype, grade
of differentiation and clinical stage. We conclude that
point mutations at codon 12 of KRAS oncogene are 
a relatively common event in endometrial carcinogen-
esis, but their prognostic value is limited.
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Table 2. KRAS gene mutations in the examined endometrial
lesions.
